Efforts to identify reliable Parkinson’s biomarkers have produced an impressive shortlist—CSF α-syn seeds, plasma neurofilament light chain (NfL), dopamine-transporter imaging, metabolomic and proteomic panels—yet most fall short when confronted with heterogeneity of stage, phenotype, and assay platform. This evidence concerns the gene SLC6A3 and Parkinson disease.